Acurx Announces Positive Phase 2A Clinical Trial Results for Ibezapolstat in C. difficile Infection at Prominent International Conference - PRNewswire
High-throughput screening identifies a novel natural product-inspired scaffold capable of inhibiting Clostridioides difficile in vitro
Clostridioides difficile is an enteric pathogen responsible for causing debilitating diarrhea, mostly in hospitalized patients. The bacterium exploits on microbial dysbiosis induced by the use of antibiotics to establish infection that ranges from mild watery diarrhea to pseudomembranous colitis. Th …
Investigational Clostridioides Difficile Therapy Demonstrates Superiority Over Placebo - Contagionlive.com
Ferring Pharmaceuticals and Rebiotix reported results from a trial on their therapy, RBX2660, which shows promise as a Clostridioides difficile infection (CDI) treatment.
C. difficile Infection Therapeutic Drug Market to Witness ... C. difficile Infection Therapeutic Drug Market to Witness Growth Acceleration by Top Key Players – Pfizer Inc., Astellas ....
In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection
Clostridioides difficile infections (CDIs) are an urgent public health threat worldwide and are a leading cause of morbidity and mortality in healthcare settings. The increasing incidence and severity of infections combined with the scarcity of effective anti-CDI agents has made treatment of CDI ver …
Novel Antibiotic for C diff Enters Phase 2 Clinical Trial - Contagionlive.com
Recruitment for a phase 2 trial of a novel antibiotic against Clostridium difficile (C diff) is proceeding after phase 1 demonstrated safety and tolerability.
The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1 open-label single-group trial - The Lancet
Microbome for c diff works
An investigational microbiome-based therapeutic for C difficile was found to exert continued efficacy 3 months after administration.